PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)

Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67228-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)67228-2/fulltext
Title : PAR19 CRITERIA-BASED INTERPRETATION OF SF-36 IMPROVEMENTS FROM ADALIMUMAB PLUS METHOTREXATE (MTX) COMBINATION THERAPY VS. MTX ALONE IN EARLY RHEUMATOID ARTHRITIS (RA)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67228-2&doi=10.1016/S1098-3015(10)67228-2
First page :
Section Title :
Open access? : No
Section Order : 452
Categories :
Tags :
Regions :
ViH Article Tags :